Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | unknown | PO / MO |
A patient took the first two doses of Vivotif on two consecutive days; Case reference number US-BN-2025-000324 is a spontaneous case initially received from nurse via Communication (reference number: USBAV25-0506) on 06-Mar-2025 and concerns adult female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 05-Mar-2025, the patient took the first dose of Vivotif (batch number: unknown) orally, at unknown dose, for unknown indication. On 06-Mar-2025, one day after first dose of Vivotif, patient took second dose of Vivotif (batch number: unknown) orally, at unknown dose (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due Vivotif. No further information was provided.; Reporter's Comments: This case report concerns adult female patient of unspecified age who took second dose of Vivotif orally, one day after first dose of Vivotif,at unknown dose, for unknown indication which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: This case report concerns adult female patient of unspecified age who took second dose of Vivotif orally, one day after first dose of Vivotif,at unknown dose, for unknown indication which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: NONE